Article
New NCCN Guidelines Call for AI-Based Mammogram Risk Assessment at 35
New guidelines from the National Comprehensive Cancer Network® champion artificial intelligence in breast cancer screening
Clairity’s approach is grounded in decades of work focused on the early identification of cancer. Review recent examples of research and news regarding Clairity and Clairity founder Dr. Connie Lehman, MD, PhD, related to computer aided diagnosis, deep learning, artificial intelligence, density assessment, predictive risk models, effective imaging workflow and risk-based triage.
New guidelines from the National Comprehensive Cancer Network® champion artificial intelligence in breast cancer screening
Until now, understanding breast cancer risk outside of family history and BRCA mutations has been challenging. Innovations in AI technology might help predict cancer before it even takes root.
Major paradigm shift incorporates five-year risk assessment and identifies increased-risk women beginning at age 35
Boston AI startup Clairity is providing assessments of the chance of getting breast cancer for patients at a clinic of Beth Israel Deaconess Medical Center.
Beth Israel Deaconess Medical Center (BIDMC) in Boston has administered its first clinical cancer risk score using Clairity Breast, a U.S. Food and Drug Administration (FDA)-authorized AI tool for mammogram-based breast cancer risk assessment.
Beth Israel Deaconess Medical Center on Friday rolled out an AI-driven technology that detects the risk of developing breast cancer in the next five years.
The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in women’s health. Clairity Breast, a product of Clairity Inc., is the first FDA-authorized, image-based artificial intelligence tool designed to assess a woman’s future risk of breast cancer. This AI technology derives the score directly and exclusively from a woman’s mammogram, transforming a diagnostic tool into a predictive one.
TIME’s Annual List Recognizes 100 of the World’s Most Influential Leaders in Health.
Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors.
New tech wants to graduate from detecting existing cancers to predicting future risk.
Clairity, developer of the first image-only AI model authorized by the U.S. Food and Drug Administration (FDA) that estimates a woman’s five-year risk of developing breast cancer from a routine mammogram, today announced the formation of a Strategic Advisory Board to support its product path and the broad rollout and adoption of Clairity’s predictive AI technologies at scale.
Actionable offering helps enable earlier, more personalized breast cancer interventions.
Clairity, Inc., an AI-driven precision health company pioneering image-based risk prediction, today announced the closing of a $43 million Series B financing.
During the broadcast, Dr. Connie Lehman shared a five-year breast cancer risk estimate for NBC anchor Savannah Sellers, generated from her mammogram images by the CLAIRITY BREAST AI platform.
For the first time, they will receive risk scores revealing their likelihood of developing the disease in the next five years, not based on their genetics or family history, but through features on their mammogram, visible only to an AI tool called Clairity Breast.
Routine mammograms are the mainstay of breast cancer screening. But, with a new type of analysis powered by artificial intelligence, doctors may be able to also predict whether or not you’ll develop breast cancer in the next few years.
About one in eight women will be diagnosed with the disease in their lifetimes. To combat that, some doctors are using AI as a tool to help them not only detect breast cancer, but also predict a woman’s risk factors.
Clairity, Inc., a company pioneering AI-powered risk prediction in human health, today announced that Founder Dr. Connie Lehman has been named to the Forbes “50 Over 50: Innovation” list.
Clairity Inc., a leader in AI-based breast cancer risk prediction, today announced that five scientific presentations featuring its FDA-authorized image-only AI model will be presented at the Radiological Society of North America (RSNA) 2025 Annual Meeting, taking place November 30 to December 4 in Chicago.
Health-tech companies are designing models that identify patients at risk of developing cancer, and who might need more screening or preventive care.
Clairity Breast is an AI-powered tool that is able to predict your risk for the disease in the next five years. Constance Lehman, M.D., Ph.D., the founder of Clairity Inc. and a Breast Cancer Research Foundation (BCRF) investigator, says that it employs deep learning, a form of AI that teaches computers to process data like the human brain.